| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 00% | ₹1,013.5 0% | 4,600 | ₹7.35 0% | 3750% |
| 3750% | ₹795 0% | 4,800 | ₹3.25 75.67% | 1250% |
| - | - | 4,850 | ₹5 0% | 2,0000% |
| - | - | 4,900 | ₹10 0% | 2500% |
| - | - | 4,950 | ₹13 -17.72% | 11,0000% |
| 1250% | ₹540 0% | 5,000 | ₹14.5 11.53% | 9,12532.72% |
| 00% | ₹511.4 0% | 5,100 | ₹27.75 0% | 4,5000% |
| - | - | 5,200 | ₹35.65 20.64% | 8,3758.06% |
| 00% | ₹477.05 0% | 5,250 | ₹21.15 0% | 5000% |
| 5,0000% | ₹281.6 1.53% | 5,300 | ₹55.15 -5.96% | 15,875-5.22% |
| 5000% | ₹304.8 0% | 5,350 | ₹90.25 0% | 4,8750% |
| 1,5009.09% | ₹241.15 -40.19% | 5,400 | ₹76.15 11% | 19,000-10.05% |
| 5,2502.43% | ₹191 -12.68% | 5,450 | ₹86.45 12.78% | 8,000-3.03% |
| 17,750-2.06% | ₹160 -8.83% | 5,500 | ₹111 7.76% | 26,3758.20% |
| 3,7503.44% | ₹135.55 -6.03% | 5,550 | ₹136.65 -27.81% | 5,25027.27% |
| 12,125-17.09% | ₹105.1 -14.62% | 5,600 | ₹174.75 0% | 8,0000% |
| 8,25013.79% | ₹88.5 -14.73% | 5,650 | ₹220 0% | 5,5000% |
| 14,87512.26% | ₹70 -17.5% | 5,700 | ₹202.9 -0.24% | 7,1250% |
| 13,0000% | ₹54.45 -3.11% | 5,750 | ₹236.75 0% | 4,0000% |
| 26,000-5.45% | ₹43 -15.68% | 5,800 | ₹271.65 -13.15% | 2,37511.76% |
| 2,500-4.76% | ₹33 -16.34% | 5,850 | - | - |
| 27,0005.88% | ₹25.4 -21.6% | 5,900 | ₹264 0% | 3750% |
| 46,500-3.87% | ₹14.65 -22.28% | 6,000 | ₹480.7 0% | 3750% |
| 2,0000% | ₹14.85 0% | 6,050 | ₹477.75 0% | 00% |
| 7,125-22.97% | ₹9.2 -16.36% | 6,100 | - | - |
| 9,125-13.09% | ₹9 3.44% | 6,150 | ₹733.1 0% | 2500% |
| 4,125-5.71% | ₹3.35 -25.55% | 6,200 | - | - |
| 6250% | ₹13.15 0% | 6,250 | - | - |
| 4,5000% | ₹3 -25.92% | 6,300 | ₹795 0% | 3750% |
| 2,7500% | ₹7 0% | 6,400 | - | - |
| - | - | 6,450 | ₹1,060 0% | 1250% |
| 2,0000% | ₹4 0% | 6,500 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
